SCHEMBL4834669

SCHEMBL4834669

COc1ccc2c(-c3ccc(C)cc3)nnc(Cl)c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
CNR1 P21554 2/20 0.45
PDE4A P27815 1/20 0.44
PDE4B Q07343 1/20 0.44
PDE4C Q08493 1/20 0.44
PDE4D Q08499 1/20 0.44
KMT2A Q03164 4/20 0.43
LMNA P02545 3/20 0.43
NPSR1 Q6W5P4 3/20 0.43
MEN1 O00255 3/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPT P10636 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MAOB P27338 2/20 0.43
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
CNR2 P34972 1/20 0.41
GPR55 Q9Y2T6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4122604 0.92 PDE4A (0.47) HTTSMN1; SMN2CNR1PDE4APDE4B
SCHEMBL4834418 0.91 CNR1 (0.45) HTTSMN1; SMN2CNR1KMT2ALMNA
SCHEMBL4834009 0.90 DHODH (0.48) HTTSMN1; SMN2CNR1PDE4APDE4B
SCHEMBL4840257 0.87 MAPK14 (0.46) HTTSMN1; SMN2PDE4APDE4BPDE4C
SCHEMBL4840317 0.87 PDE4A (0.46) HTTSMN1; SMN2CNR1PDE4APDE4B
SCHEMBL4843388 0.87 PDE4A (0.55) HTTSMN1; SMN2CNR1PDE4APDE4B
SCHEMBL4845442 0.87 PDE4A (0.57) HTTSMN1; SMN2PDE4APDE4BPDE4C
SCHEMBL4834614 0.86 PDE4A (0.40) HTTSMN1; SMN2CNR1PDE4APDE4B
SCHEMBL4834709 0.85 CNR1 (0.45) HTTSMN1; SMN2CNR1PDE4APDE4B
SCHEMBL4842181 0.85 PDE4A (0.43) PDE4APDE4BPDE4CPDE4DLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423030-B2 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof SANOFI-AVENTIS (FR) 2008-09-09 US disclosed
EP-1737840-B1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-09-12 EP disclosed
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-05-03 US disclosed
EP-1737840-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-01-03 EP disclosed
WO-2005103033-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF CYP11B2, CYP11B1, GOT2 HTT 743/4885SMN1; SMN2 1239/4885CNR1 1058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.